An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Investigational Treatment Acquiring Popularity Via Social Media
The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged weight-reducing properties. Viewers are urged to message these profiles privately for supplier links, while also obtaining promotional offers.
Thriving Trade on Social Networks
Separately, a flourishing trade exists on Telegram, where communities with thousands of members share “before and after” images, administration instructions and assertions of rapid British shipping. Vendors promote the substance there before directing customers to WhatsApp for transactions.
Learning About Retatrutide
Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.
Healthcare Professionals Express Worries
However, physicians and chemists have cautions that the distribution of what is still an unapproved medication in the UK is worrisome and could result in users administering substances of unknown origin.
Several experts stated the demand for retatrutide could be connected to the increasing cost of licensed weight loss treatments such as Mounjaro.
Regulatory Position and Enforcement
Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.
Several influencers attempt to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still breach medicines, marketing, and consumer laws, risking penalties, prosecution or imprisonment.
Platform Reaction and Content Removal
According to the social media company, the platform has removed violative material and banned related keywords and query recommendations. The company stated it was committed to keeping the service secure and allocating resources in strengthening enforcement strategies.
Online Trading Operations
Research also found communities with up to 9,000 members marketing retatrutide using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly brings up groups with numerous of members, populated with photos of slimming results, positive reviews and step-by-step guides for preparing or administering at home.
Within moments of joining one group, a seller posted WhatsApp details, where most transactions occur. The vendor provided an instruction manual and guaranteed delivery within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None inquired about body mass, medical conditions or past usage.
Item Information and Costs
Within these communities, messages display black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at home with purified liquid, or pre-filled injectors typically priced at 160 pounds for 20 milligrams. When questioned how much time a injector should be used, sellers give conflicting responses ranging from a several days to “depends on your body”.
Platform Oversight and Safety Actions
A representative for Telegram said it actively moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are injecting materials they can’t verify. Even if the science behind this drug is sound, these digital products may not contain what they advertise,” stated Jason Murphy, the head of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in demand to current cost increases for authorized weight-loss drugs such as Mounjaro. “With prices increasing, individuals are turning to social media. But fake injections are extremely risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she explained.
Her team has previously seen patients harmed by self-injection from unverified suppliers. “We understand the frustration, but purchasing from Telegram or communication platforms is gambling with your health,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”
Producer Statement
A spokesperson from Eli Lilly stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly investigational substance not yet approved … may subject users to possibly significant health risks”.
